Clinical Trials on HIV Infections

Total 61533 results

Emory University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Researching Alveolar Macrophage Improvements With Supplements in HIV (RAISe)

HIV-1 Infection

United States
Fundación Huésped
Ministry of Science and Technology,Argentine; National AIDS and STD programme... and other collaborators

Completed

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (ANDES)

HIV-1 Infection

Argentina
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients (VIH-2)

HIV-2 Infection

France
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

HIV-1 Infection

United States, Puerto Rico
Michael Hoelscher
German Federal Ministry of Education and Research; ANRS, Emerging Infectious... and other collaborators

Completed

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen (FATI-01)

HIV-1 Infection

Côte D'Ivoire, Tanzania
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women

HIV-1 Infection

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
University Hospital, Strasbourg, France

Unknown

Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation

HIV-1 Infection

France
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (CM HIV-Core008)

HIV-1-infection | HIV Vaccine

United States
Bayside Health
The Peter Doherty Institute for Infection and Immunity

Recruiting

Optimising Cohorts for HIV Cure Interventions (HI-ART)

HIV-1-infection

Australia
Institut National de la Santé Et de la Recherche...

Recruiting

Quantification of Antisense HIV RNA in Patients

HIV-1-infection

France
Peking Union Medical College Hospital

Not yet recruiting

A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients

HIV-1-infection
Societa' Italiana Di Malattie Infettive E Tropicali

Recruiting

Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) (EDOLAS)

HIV-1-infection

Italy
Fundación Pública Andaluza para la Investigación...

Not yet recruiting

Impact of V106I on Resistance to Doravirine (V106IFC)

HIV-1-infection
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
David Ho
Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative; The...

Completed

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

HIV-1-infection

United States
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
Association de Recherche en Virologie et Dermatologie

Completed

Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES) (LAMRES)

HIV-1-infection

France
University of Colorado, Denver

Completed

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

HIV-1-infection

United States
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Imperial College London

Active, not recruiting

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens (EAVI2020_01)

HIV-1-infection

United Kingdom
CytoDyn, Inc.

Active, not recruiting

PRO 140 in Treatment-Experienced HIV-1 Subjects

HIV-1-infection

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda

HIV-1-infection

Uganda
United BioPharma
National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaborators

Completed

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

HIV-1 Infection

Taiwan
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

France, Spain, Germany, United Kingdom, United States, Puerto Rico, Belgium, Canada, Italy, Dominican Republic
Viriom

Completed

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

HIV-1-infection

Russian Federation
Gilead Sciences

Completed

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

HIV-1-infection

United States, Puerto Rico, France, Germany, Austria, Canada
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

HIV-1 Infection

China
Viriom

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

HIV-1-infection

Russian Federation
Kirby Institute

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients (HSCT-HIV)

HIV-1 Infection

Australia
University of Washington
National Institute of Mental Health (NIMH); Bill and Melinda Gates Foundation; Kenya Medical Research Institute and other collaborators

Completed

The Partners Scale-Up Project

HIV-1-infection

Kenya
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (BRAAVE 2020)

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
Azienda Ospedaliera Universitaria Integrata Verona

Completed

Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction

HIV-1-infection

Italy
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

HIV-1 Infection

Germany, Romania
Erasmus Medical Center

Completed

LRAs United as a Novel Anti-HIV Strategy. (LUNA)

HIV-1-infection

Netherlands
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

HIV-1 Infection

United States
Gilead Sciences

Terminated

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

HIV-1-infection

Uganda, Zimbabwe
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic

3

Subscribe